Clal Biotechnology Industries Ltd. (CBI.TA)
ILA 35.6
(-0.84%)
ILA 35.6
(-0.84%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | - ILS | -92.84% |
| 2022 | 100.61 Million ILS | 199.42% |
| 2021 | -101.2 Million ILS | -20.99% |
| 2020 | -83.64 Million ILS | -4.73% |
| 2019 | -79.86 Million ILS | 12.2% |
| 2018 | -90.96 Million ILS | -73.0% |
| 2017 | -52.58 Million ILS | 70.52% |
| 2016 | -178.34 Million ILS | 1.07% |
| 2015 | -180.27 Million ILS | 71.69% |
| 2014 | -636.71 Million ILS | -327.11% |
| 2013 | -149.07 Million ILS | -42.5% |
| 2012 | -104.61 Million ILS | 32.26% |
| 2011 | -154.42 Million ILS | -19.13% |
| 2010 | -129.62 Million ILS | -5.7% |
| 2009 | -122.63 Million ILS | -35.73% |
| 2008 | -90.34 Million ILS | -143.34% |
| 2007 | -37.12 Million ILS | -118.06% |
| 2006 | -17.02 Million ILS | 15.73% |
| 2005 | -20.2 Million ILS | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | -2.82 Million ILS | -102.3% |
| 2023 Q4 | -2.26 Million ILS | 0.0% |
| 2023 Q2 | -2.82 Million ILS | 0.0% |
| 2023 Q3 | -2.26 Million ILS | 19.74% |
| 2023 FY | 7.2 Million ILS | -92.84% |
| 2022 Q2 | -23.38 Million ILS | -5.67% |
| 2022 Q3 | -8.22 Million ILS | 64.82% |
| 2022 FY | 100.61 Million ILS | 199.42% |
| 2022 Q4 | 122.58 Million ILS | 1589.67% |
| 2022 Q1 | -22.13 Million ILS | 44.0% |
| 2021 Q2 | -21.65 Million ILS | -12.93% |
| 2021 FY | -101.2 Million ILS | -20.99% |
| 2021 Q4 | -39.52 Million ILS | -90.59% |
| 2021 Q3 | -20.73 Million ILS | 4.24% |
| 2021 Q1 | -19.17 Million ILS | -13.68% |
| 2020 Q4 | -16.86 Million ILS | 13.29% |
| 2020 FY | -83.64 Million ILS | -4.73% |
| 2020 Q1 | -25.3 Million ILS | 33.2% |
| 2020 Q2 | -22.01 Million ILS | 12.99% |
| 2020 Q3 | -19.45 Million ILS | 11.63% |
| 2019 Q4 | -37.87 Million ILS | -13.37% |
| 2019 Q2 | 41.41 Million ILS | 182.84% |
| 2019 FY | -79.86 Million ILS | 12.2% |
| 2019 Q1 | -49.99 Million ILS | -115.9% |
| 2019 Q3 | -33.41 Million ILS | -180.67% |
| 2018 Q3 | -32.18 Million ILS | -1531.08% |
| 2018 Q1 | -37.87 Million ILS | 9.42% |
| 2018 FY | -90.96 Million ILS | -73.0% |
| 2018 Q4 | -23.15 Million ILS | 28.05% |
| 2018 Q2 | 2.24 Million ILS | 105.94% |
| 2017 Q4 | -41.81 Million ILS | -178.71% |
| 2017 Q2 | -28.89 Million ILS | 27.11% |
| 2017 Q1 | -39.64 Million ILS | 21.13% |
| 2017 FY | -52.58 Million ILS | 70.52% |
| 2017 Q3 | 53.12 Million ILS | 283.81% |
| 2016 Q2 | -48.83 Million ILS | -63.19% |
| 2016 Q1 | -29.92 Million ILS | 59.3% |
| 2016 Q3 | -40.36 Million ILS | 17.34% |
| 2016 FY | -178.34 Million ILS | 1.07% |
| 2016 Q4 | -50.27 Million ILS | -24.54% |
| 2015 Q3 | -27.5 Million ILS | 27.76% |
| 2015 FY | -180.27 Million ILS | 71.69% |
| 2015 Q2 | -38.07 Million ILS | 7.52% |
| 2015 Q4 | -73.52 Million ILS | -167.32% |
| 2015 Q1 | -41.17 Million ILS | 92.38% |
| 2014 Q2 | -20.78 Million ILS | 57.32% |
| 2014 Q1 | -48.71 Million ILS | -24.91% |
| 2014 FY | -636.71 Million ILS | -327.11% |
| 2014 Q4 | -540.51 Million ILS | -1279.33% |
| 2014 Q3 | -39.18 Million ILS | -88.51% |
| 2013 Q2 | -34.52 Million ILS | -21.11% |
| 2013 Q3 | -46.58 Million ILS | -34.91% |
| 2013 FY | -149.07 Million ILS | -42.5% |
| 2013 Q4 | -38.99 Million ILS | 16.28% |
| 2013 Q1 | -28.5 Million ILS | 22.11% |
| 2012 Q3 | -21.29 Million ILS | -11.74% |
| 2012 Q4 | -36.59 Million ILS | -71.89% |
| 2012 FY | -104.61 Million ILS | 32.26% |
| 2012 Q1 | -27.66 Million ILS | 0.0% |
| 2012 Q2 | -19.05 Million ILS | 31.13% |
| 2011 FY | -154.42 Million ILS | -19.13% |
| 2010 FY | -129.62 Million ILS | -5.7% |
| 2009 FY | -122.63 Million ILS | -35.73% |
| 2008 FY | -90.34 Million ILS | -143.34% |
| 2007 FY | -37.12 Million ILS | -118.06% |
| 2006 FY | -17.02 Million ILS | 15.73% |
| 2005 FY | -20.2 Million ILS | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Matricelf Ltd | -12.59 Million ILA | 100.0% |